Results 71 to 80 of about 10,523 (190)

PCSK9 inhibitors [PDF]

open access: yesNursing Critical Care, 2019
PCSK9 inhibitors.
openaire   +2 more sources

Genomic and Sex Contributions to Interindividual Variability in Pitavastatin Bioavailability

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Aim This study investigates pharmacogenetic determinants of pitavastatin disposition using a candidate‐gene approach. Methods In 48 healthy volunteers, 138 variants across 40 genes involved in drug metabolism and transport were analysed to assess their relationship with pitavastatin pharmacokinetics, alongside the influence of sex and ...
Eva González‐Iglesias   +7 more
wiley   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

open access: yesMolecular Oncology, Volume 20, Issue 6, Page 1556-1590, June 2026.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova   +25 more
wiley   +1 more source

Cholesterol and stroke: role of PCSK9 inhibitors

open access: yesNeurología (English Edition), 2019
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of plasma levels of low density lipoprotein cholesterol (LDLC). PCSK9 binds to the LDL receptor (LDLR), disrupts its endocytic recycling itinerary and directs it to lysosomal degradation.
L. Castilla-Guerra   +2 more
openaire   +4 more sources

A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals

open access: yesAdvanced Materials, Volume 38, Issue 33, 12 June 2026.
A cryoprotectant‐compatible nanoporous platform enables ambient‐stable and scalable delivery of gene editing therapeutics. By combining hierarchical pore architecture with optimized lyophilization chemistry, the system preserves Cas9‐RNP activity post‐freeze‐drying.
Sian Lee   +8 more
wiley   +1 more source

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

open access: yesJACC: Basic to Translational Science, 2016
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and
Elise F. Villard, PhD   +15 more
doaj   +1 more source

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang   +14 more
wiley   +1 more source

APOE and Cerebral Microbleeds: Insights Into Causal Proteins and Therapeutic Targets

open access: yesBrain and Behavior, Volume 16, Issue 6, June 2026.
This study identifies APOE as a key causal protein for cerebral microbleeds (CMBs). By integrating Mendelian randomization (MR) and colocalization analysis of the plasma proteome from UKB‐PPP and deCODE datasets, we provide genetic evidence that circulating APOE levels are causally linked to CMB susceptibility. Furthermore, protein–protein interaction (
Lei Yang   +8 more
wiley   +1 more source

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundWe sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and ResultsWe performed a systematic review and meta‐analysis of randomized controlled trials
Aris Karatasakis   +11 more
doaj   +1 more source

Homeobox B13 activates the hypoxia‐inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma

open access: yesJournal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Lactylation‐mediated metabolism reprogramming in HCC sorafenib resistance. In sorafenib‐resistant hepatocellular carcinoma (HCC) cells, lactate accumulation drives histone H3 lysine 18 lactylation (H3K18la). This modification is specifically enriched in the promoter region of homeobox B13 (HOXB13), activating HOXB13 transcription and upregulating its ...
Qingqing Xie   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy